PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 53 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $0 | – | 193 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 193 | +19200.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 1 | -99.7% | 0.00% | – |
| Q4 2021 | $1,000 | -94.1% | 299 | -94.6% | 0.00% | – |
| Q3 2021 | $17,000 | -34.6% | 5,496 | -22.2% | 0.00% | – |
| Q2 2021 | $26,000 | -66.2% | 7,065 | -68.1% | 0.00% | – |
| Q1 2021 | $77,000 | +220.8% | 22,170 | +214.0% | 0.00% | – |
| Q4 2020 | $24,000 | +20.0% | 7,060 | +24.6% | 0.00% | – |
| Q3 2020 | $20,000 | -39.4% | 5,667 | -21.0% | 0.00% | – |
| Q2 2020 | $33,000 | +135.7% | 7,171 | +73.5% | 0.00% | – |
| Q1 2020 | $14,000 | -50.0% | 4,133 | -12.6% | 0.00% | – |
| Q4 2019 | $28,000 | +27.3% | 4,728 | -13.6% | 0.00% | – |
| Q3 2019 | $22,000 | -37.1% | 5,474 | +100.8% | 0.00% | – |
| Q2 2019 | $35,000 | -5.4% | 2,726 | -29.2% | 0.00% | – |
| Q1 2019 | $37,000 | – | 3,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |